The president has raised entry fees at many of his resorts, which attract donors seeking to influence White House policy.

Iluzanebart (VGL101), Vigil’s monoclonal antibody program, is not being acquired by Sanofi, and its return to Amgen, the original licensor, and the termination of the exclusive license agreement with ...